Catalyst Pharmaceuticals Inc. announced that it has entered into a definitive agreement with Eisai Co., Ltd. (Eisai) under which Catalyst will acquire the U.S. rights for FYCOMPA(R) (perampanel) CIII and an exclusive option period to review, evaluate and negotiate to acquire a rare epilepsy asset currently in Eisai's pipeline. The acquisition adds a highly complementary and established marketed product in neurology that diversifies Catalyst's commercial product portfolio and paves the way for further expansion into other rare neurological diseases that address critical unmet medical needs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,240 JPY | -0.30% | +5.74% | -11.51% |
Apr. 24 | Biogen beats quarterly profit estimates, Alzheimer's drug sales jump | RE |
Apr. 23 | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.51% | 11.54B | |
+24.35% | 653B | |
+25.35% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+12.79% | 233B | |
+5.36% | 201B | |
-9.94% | 193B | |
-6.47% | 144B |
- Stock Market
- Equities
- 4523 Stock
- News Eisai Co., Ltd.
- Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA(R) CIII from Eisai Co., Ltd